Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?

In English

Författare

Summary, in English

In recent years, scientists have advocated the use of targeted therapies in the form of drugs that modulate genes and proteins that are directly associated with cancer progression and metastasis. Malignant melanoma is a dreadful cancer type that has been associated with the rapid dissemination of primary tumors to multiple sites, including bone, brain, liver and lungs. The discovery that approximately 40%-50% of malignant melanomas contain a mutation in BRAF at codon 600 gave scientists a new approach to tackle this disease. However, clinical studies on patients have shown that although BRAFi (BRAF inhibitors) trigger early anti-tumor responses, the majority of patients later develop resistance to the therapy. Recent studies have shown that WNT5A plays a key role in enhancing the resistance of melanoma cells to BRAFi. The focus of the current review will be on melanoma development, signaling pathways important to acquired resistance to BRAFi, and why WNT5A inhibitors are attractive candidates to be included in combinatorial therapies for melanoma.

Avdelning/ar

Publiceringsår

2015

Språk

Engelska

Sidor

1900-1924

Publikation/Tidskrift/Serie

Cancers

Volym

7

Issue

3

Dokumenttyp

Artikel i tidskrift

Förlag

MDPI AG

Ämne

  • Cancer and Oncology

Status

Published

Forskningsgrupp

  • Experimental Pathology, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 2072-6694